AbbVie Inc. (ABBV) earnings on April 29, 2026
Prior outlook: Pessimistic Outcome: Missed
The stock price increased after the company's earnings report, closing up over 3%. This happened even though there was some negative sentiment beforehand.
ABBV price around the earnings
211.32
Change: +3.6%
2026-04-30, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Missed
Analysts positive, but stock weakness and earnings risk.
Despite positive analyst ratings, AbbVie's stock is showing significant weakness, underperforming the market considerably over the last month. There's elevated risk around upcoming earnings due to a history of mixed results and potential regulatory concerns.
Context analyzed before publication
- Summary
- Analysts positive, but stock weakness and earnings risk.
- Reasoning
- Despite positive analyst ratings, AbbVie's stock is showing significant weakness, underperforming the market considerably over the last month. There's elevated risk around upcoming earnings due to a history of mixed results and potential regulatory concerns, suggesting the scenario is a key factor.
- Playbook
- Given the negative stock performance and earnings risks, the scenario suggests a clearer context of improvement is a key factor. The upcoming earnings and any regulatory news are key factors.
- Trend
- Expert opinion deteriorating, negative trend developing.
Analysts
Drivers
-
Analysts
Positive
Analysts maintain a buy rating with a price target that points to an optimistic scenario. They anticipate stable revenue growth for the company.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.81
- Analysts covering the stock
- 30
- Average price target
- 249.27
- Lowest price target
- 184
- Highest price target
- 294
- Upside to price target
- 26.1%
- Revenue growth
- 10%
- Forward EPS
- 16.08
- Trailing EPS
- 2.37
- Analyst moves in the last 60 days
- 4
- Strong buy: 8
- Buy: 15
- Hold: 9
- Sell: 0
- Strong sell: 0
- Strong buy
- 8
- Buy
- 15
- Hold
- 9
- Sell
- 0
- Strong sell
- 0
- April 23, 2026 · Piper Sandler: Maintains rating (Overweight → Overweight)
- April 21, 2026 · Canaccord Genuity: Initiates coverage (Buy)
- April 10, 2026 · Guggenheim: Maintains rating (Buy → Buy)
- April 8, 2026 · Cantor Fitzgerald: Maintains rating (Overweight → Overweight)
News and sentiment
Drivers
-
News & sentiment
Positive
The company has a potential pipeline catalyst with its application for a new drug targeting alopecia. This could be a positive development for future growth.
Evidence
Sentiment
- Sentiment
- Cautious
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (10)
- AbbVie Files Application With FDA For Upadacitinib To Treat Adults, Adolescents With Severe Alopecia Areata — Benzinga
- AbbVie Announces Topline Results From The Phase 3B/4 Head-to-Head Select-Switch Study Evaluating The Efficacy And Safety Of Upadacitinib — Benzinga
- AbbVie Partner EvolveImmune Announces Nomination Of A Development Candidate Against A Solid Tumor Target, Achievement Of This Pre-Defined Preclinical Milestone Triggers An $18M Milestone Payment To The Company — Benzinga
- AbbVie Submits FDA Application For SKYRIZI Subcutaneous Induction In Crohn's Disease Backed By Phase 3 Data — Benzinga
- AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug — Benzinga
- AbbVie Announces It Has Received A Complete Response Letter From the FDA Regarding Biologics License Application For TrenibotulinumtoxinE; FDA Requests Additional Information About Manufacturing Processes, Does Not Identify Any Safety Or Efficacy Concerns And Does Not Request Additional Clinical Studies — Benzinga
- Piper Sandler Maintains Overweight on AbbVie, Lowers Price Target to $294 — Benzinga
- AbbVie Investing $1.4B To Construct Pharmaceutical Production Campus In Durham, North Carolina — Benzinga
- Canaccord Genuity Initiates Coverage On AbbVie with Buy Rating, Announces Price Target of $262 — Benzinga
- AbbVie Expands Collaboration With BioLabs To Support Its BioLabs University Of Toronto — Benzinga
Technicals
Drivers
-
Technical
Negative
The stock's recent performance shows significant underperformance compared to the broader market. This indicates a negative trend and weak relative strength over the past 30 days.
Evidence
- Average true range (ATR)
- 2.2%
- Distance to 52-week high
- -19.3%
- 14-day change (14d)
- -7.0%
- 30-day change
- -10.2%
- 30-day relative strength
- -16.5%
- Benchmark change
- +6.4%
- Nearest support
- 196.5
- Nearest resistance
- 223.18
- Volume accumulation ratio
- 0.9
Trends
Evidence
- Average earnings surprise
- -28.3%
- February 4, 2026: actual EPS 1.02 vs estimate 2.87 (surprise -64.5%)
- October 31, 2025: actual EPS 1.86 vs estimate 1.78 (surprise +4.2%)
- July 31, 2025: actual EPS 0.52 vs estimate 1.17 (surprise -55.6%)
- April 25, 2025: actual EPS 2.46 vs estimate 2.4 (surprise +2.6%)
Expected move
Drivers
-
Past earnings
Negative
The company has a history of mixed earnings results, with a 50% beat rate and significant negative surprises on average. This points to elevated risk surrounding future earnings.
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 4.1%
- 75th percentile move
- 4.7%
- 90th percentile move
- 6.1%
- Up / down moves
- 9 / 10
- Average up move
- +3.5%
- Average down move
- -4.1%
Monitoring and close
What AbbVie Inc. reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Missed
- Consolidated
- +3.6%
- Max favorable move (MFE)
- 0%
- Max adverse move (MAE)
- 5.4%